USANA Health Sciences (USNA) Set to Release Quarterly Earnings on Tuesday

Key Points

• USANA is expected to report Q3 2026 results after the market closes Tuesday, November 3. Analysts forecast earnings of $0.11 per share on revenue of $217.42 million, with the earnings call scheduled for November 4.
• The company’s previous quarter fell well short of expectations, reporting a $0.07 per-share loss versus consensus EPS of $0.43 and revenue of $223.27 million versus estimates of $235 million.
• Analyst sentiment remains cautious: USANA has an average “Reduce” rating, while shares have declined from a 12-month high of $23.59 to around $14.04.

USANA Health Sciences (NYSE:USNA - Get Free Report) will likely be issuing its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to announce earnings of $0.11 per share and revenue of $217.42 million for the quarter. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. Interested persons can check the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 11:00 AM ET.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.50). USANA Health Sciences had a positive return on equity of 3.41% and a negative net margin of 2.43%. The company had revenue of $223.27 million for the quarter, compared to analysts' expectations of $235.00 million. On average, analysts expect USANA Health Sciences to post $0.76 EPS for the current fiscal year and $1.77 EPS for the next fiscal year.

USANA Health Sciences Trading Up 0.6%

Shares of USNA stock opened at $14.04 on Tuesday. The company has a market capitalization of $259.46 million, a price-to-earnings ratio of -11.60, a PEG ratio of 1.53 and a beta of 0.68. The firm has a 50-day moving average price of $14.45 and a 200 day moving average price of $18.24. USANA Health Sciences has a twelve month low of $12.57 and a twelve month high of $23.59.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Zacks Research upgraded shares of USANA Health Sciences from a "strong sell" rating to a "hold" rating in a report on Monday, October 5th. Weiss Ratings reissued a "sell (d)" rating on shares of USANA Health Sciences in a research report on Monday, September 21st. Finally, Wall Street Zen downgraded shares of USANA Health Sciences from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Reduce".

About USANA Health Sciences

USANA Health Sciences, Inc develops and sells nutritional supplements, healthy foods and personal-care products through a direct-selling business model. Its product portfolio includes vitamins and mineral supplements, meal-replacement and snack products, sports nutrition offerings, and skincare products marketed under the USANA and related brands.

Founded in 1992 by microbiologist and immunologist Myron W. Wentz, the company is headquartered in Salt Lake City, Utah. USANA distributes its products through a network of independent associates and preferred customers rather than primarily through traditional retail channels.

The company serves customers in markets across the Americas, Asia-Pacific and Europe, with a significant presence in countries including the United States, Canada, Australia, New Zealand, China, Hong Kong, Japan, South Korea, the Philippines, Singapore, Malaysia and Thailand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.